{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:50:33Z","timestamp":1740142233625,"version":"3.37.3"},"reference-count":28,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC0845400","2017YFC1700200","2017YFC1702000"],"award-info":[{"award-number":["2020YFC0845400","2017YFC1700200","2017YFC1702000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81922070","81973286","81874324","81702995","U1608283"],"award-info":[{"award-number":["81922070","81973286","81874324","81702995","U1608283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic\/Technology Research Leader","doi-asserted-by":"publisher","award":["18XD1403600"],"award-info":[{"award-number":["18XD1403600"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018617","name":"LiaoNing Revitalization Talents Program","doi-asserted-by":"publisher","award":["XLYC1907103"],"award-info":[{"award-number":["XLYC1907103"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017683","name":"Dalian Science and Technology innovation fund","doi-asserted-by":"publisher","award":["2018J12SN065"],"award-info":[{"award-number":["2018J12SN065"]}],"id":[{"id":"10.13039\/501100017683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hypericin is the main active ingredient of St. John\u2019s wort, a Chinese herb commonly used\nfor treating depression. Previous studies shown that hypericin can strongly inhibit human cytochrome P450 (CYP)\nenzyme activities; however, its potential interactions that inhibit human carboxylesterases 2 (hCE2) are unclear.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Purpose:<\/jats:title>\n<jats:p>This study aimed to investigate the inhibitory effect of hypericin on hCE2.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The inhibition mechanism of hypericin on hCE2 was studied by using N-(2-butyl-1,3-dioxo-2,3-dihydro-\n1H-phenalen-6-yl)-2-chloroacetamide (NCEN). The type of inhibition of hypericin on hCE2 and the corresponding\ninhibition constant (Ki) value were determined. The inhibition of hypericin on hCE2 in living cells was discussed.\nThe risk of herb-drug interactions (HDI) of hypericin in vivo was predicted by estimating the area under the drug\nconcentration-time curve (AUC) in the presence or absence of hypericin. To understand the inhibition mechanism of\nhypericin on the activity of hCE2 in-depth, molecular docking was performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The half-maximal inhibitory concentration (IC50) values of hypericin against the hydrolysis of NCEN and\nirinotecan (CPT-11) were calculated to be 26.59 \u03bcM and 112.8 \u03bcM, respectively. Hypericin inhibited the hydrolysis\nof NCEN and CPT-11. Their Ki values were estimated as 10.53 \u03bcM and 81.77 \u03bcM, respectively. Moreover, hypericin\ndistinctly suppressed hCE2 activity in living cells. In addition, the AUC of hCE2 metabolic drugs with metabolic\nsites similar to NCEN was estimated to increase by up to 5 % in the presence of hypericin. More importantly, the\nexposure of CPT-11 in the intestinal epithelium was predicted to increase by 2 % - 69 % following the oral coadministration\nof hypericin. Further, molecular simulations indicated that hypericin could strongly interact with\nASP98, PHE307, and ARG355 to form four hydrogen bonds within hCE2.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These findings regarding the combination of hypericin-containing herbs and drugs metabolized by\nhCE2 are of considerable clinical significance.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200223666220202093303","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T04:47:51Z","timestamp":1643950071000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Substrate-dependent Inhibition of Hypericin on Human Carboxylesterase 2: Implications\nfor Herb-drug Combination"],"prefix":"10.2174","volume":"23","author":[{"given":"Dalong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key\nLaboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key\nLaboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Dalian Institute of\nChemical Physics, Chinese Academy of Sciences, Dalian, 116023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Life Science and Medicine, Dalian University of\nTechnology, Panjin, 124221, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongyi","family":"Dou","sequence":"additional","affiliation":[{"name":"School of Life Science and Medicine, Dalian University of\nTechnology, Panjin, 124221, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbo","family":"Ge","sequence":"additional","affiliation":[{"name":"Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional\nChinese Medicine, Shanghai, 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key\nLaboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key\nLaboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key\nLaboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key\nLaboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, 116044, China"},{"name":"Provincial Key\nLaboratory for Pharmacokinetics and Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jep.2015.04.053","volume":"169","author":"Zhai X.J.","year":"2015","unstructured":"Zhai X.J.; Chen F.; Chen C.; Zhu C.R.; Lu Y.N.; LC-MS\/MS based studies on the anti-depressant effect of hypericin in the chronic unpredictable mild stress rat model. J Ethnopharmacol 2015,169,363-369","journal-title":"J Ethnopharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12935-016-0279-4","volume":"16","author":"Mirmalek S.A.","year":"2016","unstructured":"Mirmalek S.A.; Azizi M.A.; Jangholi E.; Yadollah-Damavandi S.; Javidi M.A.; Parsa Y.; Parsa T.; Salimi-Tabatabaee S.A.; Ghasemzadeh Kolagar H.; Alizadeh-Navaei R.; Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line. Cancer Cell Int 2016,16(1),3","journal-title":"Cancer Cell Int"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1128\/AAC.45.2.517-524.2001","volume":"45","author":"Jacobson J.M.","year":"2001","unstructured":"Jacobson J.M.; Feinman L.; Liebes L.; Ostrow N.; Koslowski V.; Tobia A.; Cabana B.E.; Lee D.; Spritzler J.; Prince A.M.; Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John\u2019s wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001,45(2),517-524","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijpharm.2013.06.067","volume":"454","author":"Nafee N.","year":"2013","unstructured":"Nafee N.; Youssef A.; El-Gowelli H.; Asem H.; Kandil S.; Antibiotic-free nanotherapeutics: hypericin nanoparticles thereof for improved in vitro and in vivo antimicrobial photodynamic therapy and wound healing. Int J Pharm 2013,454(1),249-258","journal-title":"Int J Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11060-007-9514-0","volume":"87","author":"Cole C.D.","year":"2008","unstructured":"Cole C.D.; Liu J.K.; Sheng X.; Chin S.S.; Schmidt M.H.; Weiss M.H.; Couldwell W.T.; Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model. J Neurooncol 2008,87(3),255-261","journal-title":"J Neurooncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.biocel.2015.12.003","volume":"71","author":"Lin S.","year":"2016","unstructured":"Lin S.; Lei K.; Du W.; Yang L.; Shi H.; Gao Y.; Yin P.; Liang X.; Liu J.; Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism. Int J Biochem Cell Biol 2016,71,24-34","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tiv.2017.01.005","volume":"40","author":"Huntosova V.","year":"2017","unstructured":"Huntosova V.; Novotova M.; Nichtova Z.; Balogova L.; Maslanakova M.; Petrovajova D.; Stroffekova K.; Assessing light-independent effects of hypericin on cell viability, ultrastructure and metabolism in human glioma and endothelial cells. Toxicol In Vitro 2017,40,184-195","journal-title":"Toxicol In Vitro"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11307-006-0048-1","volume":"8","author":"Schipper M.L.","year":"2006","unstructured":"Schipper M.L.; Patel M.R.; Gambhir S.S.; Evaluation of firefly luciferase bioluminescence mediated photodynamic toxicity in cancer cells. Mol Imaging Biol 2006,8(4),218-225","journal-title":"Mol Imaging Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2174\/1381612053382287","volume":"11","author":"Kubin A.","year":"2005","unstructured":"Kubin A.; Wierrani F.; Burner U.; Alth G.; Gr\u00fcnberger W.; Hypericin--the facts about a controversial agent. Curr Pharm Des 2005,11(2),233-253","journal-title":"Curr Pharm Des"},{"key":"ref=10","first-page":"1157","volume":"25","author":"Slatter J.G.","year":"1997","unstructured":"Slatter J.G.; Su P.; Sams J.P.; Schaaf L.J.; Wienkers L.C.; Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997,25(10),1157-1164","journal-title":"Drug Metab Dispos"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s10637-013-0008-y","volume":"31","author":"Ait-Tihyaty M.","year":"2013","unstructured":"Ait-Tihyaty M.; Rachid Z.; Larroque-Lombard A.L.; Jean-Claude B.J.; ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity. Invest New Drugs 2013,31(6),1409-1423","journal-title":"Invest New Drugs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1124\/dmd.105.008623","volume":"34","author":"Goda R.","year":"2006","unstructured":"Goda R.; Nagai D.; Akiyama Y.; Nishikawa K.; Ikemoto I.; Aizawa Y.; Nagata K.; Yamazoe Y.; Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hy-droxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos 2006,34(5),828-835","journal-title":"Drug Metab Dispos"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bcp.2010.09.001","volume":"81","author":"Hatfield M.J.","year":"2011","unstructured":"Hatfield M.J.; Tsurkan L.; Garrett M.; Shaver T.M.; Hyatt J.L.; Edwards C.C.; Hicks L.D.; Potter P.M.; Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 2011,81(1),24-31","journal-title":"Biochem Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1124\/dmd.107.020248","volume":"36","author":"Williams E.T.","year":"2008","unstructured":"Williams E.T.; Jones K.O.; Ponsler G.D.; Lowery S.M.; Perkins E.J.; Wrighton S.A.; Ruterbories K.J.; Kazui M.; Farid N.A.; The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008,36(7),1227-1232","journal-title":"Drug Metab Dispos"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","volume":"21","author":"Fujita K.","year":"2015","unstructured":"Fujita K.; Kubota Y.; Ishida H.; Sasaki Y.; Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015,21(43),12234-12248","journal-title":"World J Gastroenterol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fphar.2017.00211","volume":"8","author":"Cui D.N.","year":"2017","unstructured":"Cui D.N.; Wang X.; Chen J.Q.; Lv B.; Zhang P.; Zhang W.; Zhang Z.J.; Xu F.G.; Quantitative evaluation of the compatibility effects of huangqin decoction on the treatment of irinotecan-induced gastrointestinal toxicity using untargeted metabolomics. Front Pharmacol 2017,8,211","journal-title":"Front Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1124\/dmd.112.044537","volume":"40","author":"Kobayashi Y.","year":"2012","unstructured":"Kobayashi Y.; Fukami T.; Shimizu M.; Nakajima M.; Yokoi T.; Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab Dispos 2012,40(6),1080-1084","journal-title":"Drug Metab Dispos"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1124\/dmd.108.021964","volume":"37","author":"Ohbuchi M.","year":"2009","unstructured":"Ohbuchi M.; Miyata M.; Nagai D.; Shimada M.; Yoshinari K.; Yamazoe Y.; Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. Drug Metab Dispos 2009,37(1),97-105","journal-title":"Drug Metab Dispos"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/ptr.6062","volume":"32","author":"Li J.N.","year":"2018","unstructured":"Li J.N.; Cao Y.F.; He R.R.; Ge G.B.; Guo B.; Wu J.J.; Evidence for shikonin acting as an active inhibitor of human carboxylesterases 2: Implications for herb-drug combination. Phytother Res 2018,32(7),1311-1319","journal-title":"Phytother Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"D313","DOI":"10.1093\/nar\/gkw1132","volume":"45","author":"Bienert S.","year":"2017","unstructured":"Bienert S.; Waterhouse A.; de Beer T.A.; Tauriello G.; Studer G.; Bordoli L.; Schwede T.; The SWISS-MODEL Repository-new features and functionality. Nucleic Acids Res 2017,45(D1),D313-D319","journal-title":"Nucleic Acids Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.bioorg.2018.01.011","volume":"77","author":"Weng Z.M.","year":"2018","unstructured":"Weng Z.M.; Ge G.B.; Dou T.Y.; Wang P.; Liu P.K.; Tian X.H.; Qiao N.; Yu Y.; Zou L.W.; Zhou Q.; Zhang W.D.; Hou J.; Characterization and structure-activity relationship studies of flavonoids as inhibitors against human carboxylesterase 2. Bioorg Chem 2018,77,320-329","journal-title":"Bioorg Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1200\/JCO.2000.18.3.659","volume":"18","author":"Takimoto C.H.","year":"2000","unstructured":"Takimoto C.H.; Morrison G.; Harold N.; Quinn M.; Monahan B.P.; Band R.A.; Cottrell J.; Guemei A.; Llorens V.; Hehman H.; Ismail A.S.; Flemming D.; Gosky D.M.; Hirota H.; Berger S.J.; Berger N.A.; Chen A.P.; Shapiro J.D.; Arbuck S.G.; Wright J.; Hamilton J.M.; Allegra C.J.; Grem J.L.; Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 2000,18(3),659-667","journal-title":"J Clin Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1124\/dmd.108.020479","volume":"36","author":"Obach R.S.","year":"2008","unstructured":"Obach R.S.; Lombardo F.; Waters N.J.; Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 2008,36(7),1385-1405","journal-title":"Drug Metab Dispos"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1002\/cncr.26123","volume":"117","author":"Couldwell W.T.","year":"2011","unstructured":"Couldwell W.T.; Surnock A.A.; Tobia A.J.; Cabana B.E.; Stillerman C.B.; Forsyth P.A.; Appley A.J.; Spence A.M.; Hinton D.R.; Chen T.C.; A phase 1\/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer 2011,117(21),4905-4915","journal-title":"Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/jsfa.1598","volume":"84","author":"Wang Z.","year":"2004","unstructured":"Wang Z.; Lin S.; Hu M.; Contents of hypericin and pseudohypericin in five commercial products of St John\u2019s wort (Hypericum perforatum). J Sci Food Agric 2004,84(5),395-397","journal-title":"J Sci Food Agric"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMoa012122","volume":"346","author":"Davidson R.","year":"2002","unstructured":"Davidson R.; Cavalcanti R.; Brunton J.L.; Bast D.J.; de Azavedo J.C.; Kibsey P.; Fleming C.; Low D.E.; Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002,346(10),747-750","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2016.04.041","volume":"378","author":"K\u00fchl A.A.","year":"2016","unstructured":"K\u00fchl A.A.; Erben U.; Cieluch C.; Spieckermann S.; Gr\u00f6ne J.; Lohneis P.; Pape U.F.; Arsenic R.; Utku N.; Tissue-infiltrating plasma cells are an important source of carboxylesterase 2 contributing to the therapeutic efficacy of prodrugs. Cancer Lett 2016,378(1),51-58","journal-title":"Cancer Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1248\/bpb.b14-00679","volume":"38","author":"Wang X.","year":"2015","unstructured":"Wang X.; Zhu H.J.; Markowitz J.S.; Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. Biol Pharm Bull 2015,38(2),292-297","journal-title":"Biol Pharm Bull"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220202093303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200761\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389200223666220202093303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:20:56Z","timestamp":1692037256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200761\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200223666220202093303","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}